https://immatics.com/

Contributing Author

Recent Articles by https://immatics.com/

Apr-21	Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting IMTX GlobeNewswire
Apr-17	PRAME-directed Cell Therapy Using Immatics' TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma IMTX GlobeNewswire
Mar-05	Immatics Announces Full Year 2025 Financial Results and Business Update IMTX GlobeNewswire
Dec-11	Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress IMTX GlobeNewswire
Dec-05	Immatics Announces $125 Million Underwritten Offering IMTX -14.24% GlobeNewswire
Nov-17	Immatics Announces Third Quarter 2025 Financial Results and Business Update IMTX -7.16% GlobeNewswire
Nov-12	Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps IMTX +16.10% GlobeNewswire
Oct-27	Immatics Appoints Amie Krause as Chief People Officer IMTX GlobeNewswire
Oct-20	Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium IMTX +11.04% GlobeNewswire
Oct-01	Immatics Appoints Venkat Ramanan as Chief Financial Officer IMTX +5.63% GlobeNewswire
Aug-13	Immatics Announces Second Quarter 2025 Financial Results and Business Update IMTX GlobeNewswire
May-31	Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma IMTX GlobeNewswire
May-13	Immatics Announces First Quarter 2025 Financial Results and Business Update IMTX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)